Rheumatologists contribute to the clinic their assessment of disease-related cardiovascular risk factors, such as disease activity or prescribed medications. “The risk factors are a little bit different and the approach may be a little bit different,” explained Dr. Gabriel.
Lara C. Pullen, PhD, is a medical writer based in the Chicago area.
ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE
Studies on the Cardiovascular Effects of the Drugs Used by Rheumatologists
- Boers M, Nurmohamed MT, Doelman CJA, et al. Influence of glucocorticoids and disease activity on total and high density lipoprotein cholesterol in patients with rheumatoid arthritis. Ann Rheum Dis. 2003;62:842–845.
- Asanuma Y, Kawai S, Aoshima H, et al. Serum lipoprotein(a) and apolipoprotein(a) phenotypes in patients with rheumatoid arthritis. Arthritis Rheum. 1999 Mar;42(3):443–447.
- Lazzerini PE, Capecchi PL, Bisogno S, et al. Reduction in plasma homocysteine level in patients with rheumatoid arthritis given pulsed glucocorticoid treatment. Ann Rheum Dis. 2003 Jul;62(7):694–695.
- del Rincón I, Battafarano DF, Restrepo JF, et al. Glucocorticoid dose thresholds associated with all-cause and cardiovascular mortality in rheumatoid arthritis. Arthritis Rheum. 2014 Feb;66(2):264–272.
- Hoekstra M, Haagsma CJ, Doelman CJ, van de Laar MA. Intermittent rises in plasma homocysteine in patients with rheumatoid arthritis treated with higher dose methotrexate. Ann Rheum Dis. 2005 Jan;64(1):141–143.
- Choi HK, Hernán MA, Seeger JD, et al. Methotrexate and mortality in patients with rheumatoid arthritis: A prospective study. Lancet. 2002 Apr 6;359(9313):1173–1177.